The online community for biotechnology industry of Switzerland.

SuisseBio has seen steady growth since 2004 and is expected to continue to expand. The Swiss biopharmaceutical market’s strength lies in the ability to carry products to the final stage of development. Switzerland ranks second in the number of pipelines in all phases according to Ernst & Young. Although Switzerland is a smaller country, its success has placed this Hotbed in the company of the world’s most successful biotechnology markets.

Join the World Discussion Forum

Click here to Search Jobs

Hotbed News
Roche (RHHBY), Merck & Co. (MRK) Extend Immunotherapy Battle To Breast Cancer Monday, October 20, 2014
Roche (RHHBY) To Spend $3.2 Billion On Basel Site Upgrade Thursday, October 23, 2014
Novartis AG (NVS)'s AIN457 Meets Primary Endpoint In Two Late Stage Studies Thursday, October 23, 2014
MRI Technique Detects Evidence Of Cognitive Decline Before Symptoms Appear, University of Geneva Reveals Tuesday, October 07, 2014
Price Tag May Be The Challenge For Novartis AG (NVS) And Juno Therapeutics' Magical Cancer Drugs Wednesday, October 08, 2014
Booming Alexion Pharmaceuticals Inc. (ALXN) Eyes European Headquarters In Zurich On Expansion Push Thursday, October 16, 2014
Novartis AG (NVS) Psoriasis Drug Secukinumab Benefits Outweighs Risk: FDA Staff Monday, October 20, 2014
Three Executives To Leave Novartis AG (NVS) After GlaxoSmithKline (GSK), Eli Lilly and Company (LLY) Deals Friday, October 10, 2014
Oxford BioMedica PLC (OXB.L) Inks Transformational $90 Million Deal With Novartis AG (NVS) Monday, October 13, 2014
Roche (RHHBY) Lucentis, Regeneron (REGN) Eylea Continue To Battle It Out In Eye Market Thursday, October 16, 2014
12345678910